Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms
Diseases · 18.12.2023 · 11 (4) · 184
DOI: 10.3390/diseases11040184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases, online erschienen am 18.12.2023. Verfasst von Qamraa H Alqahtani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deputyship for Research and Innovation, “Ministry of Education”.
Abstract (Originalsprache)
Diabetes is a ubiquitous disease that causes several complications. It is associated with insulin resistance, which affects the metabolism of proteins, carbohydrates, and fats and triggers liver diseases such as fatty liver disease, steatohepatitis, fibrosis, and cirrhosis. Despite the effectiveness of Sitagliptin (ST) as an antidiabetic drug, its role in diabetes-induced liver injury is yet to be fully investigated. Therefore, this study aims to investigate the effect of ST on hepatic oxidative injury, inflammation, apoptosis, and the mTOR/NF-κB/NLRP3 signaling pathway in streptozotocin (STZ)-induced liver injury. Rats were allocated into four groups: two nondiabetic groups, control rats and ST rats (100 mg/kg), and two diabetic groups induced by STZ, and they received either normal saline or ST for 90 days. Diabetic rats showed significant hyperglycemia, hyperlipidemia, and elevation in liver enzymes. After STZ induction, the results revealed remarkable increases in hepatic oxidative stress, inflammation, and hepatocyte degeneration. In addition, STZ upregulated the immunoreactivity of NF-κB/p65, NLRP3, and mTOR but downregulated IKB-α in liver tissue. The use of ST mitigated metabolic and hepatic changes induced by STZ; it also reduced oxidative stress, inflammation, and hepatocyte degeneration. The normal expression of NF-κB/p65, NLRP3, mTOR, and IKB-α were restored with ST treatment. Based on that, our study revealed for the first time the hepatoprotective effect of ST that is mediated by controlling inflammation, oxidative stress, and mTOR/NF-κB/NLRP3 signaling.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia.
- Department of Clinical Laboratory Science, College of Applied Medical Sciences, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia.
- Department of Histology, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia.
- Department of Clinical Medicine, Shanghai Medical College, Fudan University, Shanghai 200233, China.
ORCID-Profile: Qamraa H Alqahtani, Samiyah Alshehri, Ahlam M Alhusaini, Wedad S Sarawi, Sana S Alqarni, Iman H Hasan
Förderung
- Deputyship for Research and Innovation, “Ministry of Education”
Zitieren
APA
Alqahtani, Q. H., Alshehri, S., Alhusaini, A. M., Sarawi, W. S., Alqarni, S. S., Mohamed, R., Kumar, M. N., Al-Saab, J., & Hasan, I. H. (2023). Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms. Diseases, 11(4), 184. https://doi.org/10.3390/diseases11040184
Vancouver
Alqahtani QH, Alshehri S, Alhusaini AM, Sarawi WS, Alqarni SS, Mohamed R, et al. Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms. Diseases. 2023;11(4):184. doi:10.3390/diseases11040184
BibTeX
@article{Alqahtani2023,
author = {Alqahtani, Qamraa H and Alshehri, Samiyah and Alhusaini, Ahlam M and Sarawi, Wedad S and Alqarni, Sana S and Mohamed, Raessa and Kumar, Meha N and Al-Saab, Juman and Hasan, Iman H},
title = {Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms},
journal = {Diseases},
year = {2023},
volume = {11},
number = {4},
pages = {184},
doi = {10.3390/diseases11040184}
}
EUVIMED